Sector News

Medtronic to buy Mazor Robotics for $1.64 billion

September 21, 2018
Life sciences

Medtronic PLC said late Thursday that it plans to buy the Israel-based Mazor Robotics Ltd. for $1.64 billion in cash.

Mazor stock is up 7.5% and Medtronic fell less than 0.1% after hours. The S&P 500 index closed up 0.8%. Medtronic, a medical technology maker, said it would pay $58.50 for each American Depository Share of Mazor, which makes robotic guidance systems that are applied to medical tech.

“The Mazor team and product portfolio’s full integration into Medtronic will maximize our impact globally through Medtronic’s channels, advance our systems’ leadership position in the marketplace, and drive the realization of our vision to heal through innovation,” said Mazor CEO Ori Hadomi.

The acquisition is expected to close during Medtronic’s third fiscal quarter, which ends Jan. 25, 2019.

By Max A. Cherney

Source: MarketWatch

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend